Articles

A new laser system designed to perform four incisions, the Catalys Precision Laser system, from OptiMedica has been shown to help surgeons achieve significant improvement in precision during several critical steps of cataract surgery.

Fight for Sight has awarded six £15,000 grants to support ophthalmic research in the UK.

A round up of new products

Patients suffering from primary open-angle glaucoma (POAG) or ocular hypertension have been shown to respond better to travoprost than latanoprost according to a recent study.

Optos plc has announced its proposed acquisition of the entire issued shared capital of Opto Global Holdings for up to $14.75 million.

Volk Optical has expanded its disposable vitrectomy lens range with five new direct image lenses.

A recent study has shown that the AcrySof toric IOL is more stable and provides better vision in cataract patients with pre-existing astigmatism, compared with an AcrySof spherical IOL.

A pain relief drug (+)-pentazocine has been shown to restore retinal health in diabetic mice. It is now hoped that this action can be replicated in humans.

Corneal arcus has been associated with higher intraocular pressure (IOP) and lower central corneal thickness (CCT), according to a recent study.

i-Optics has announced the successful closure of its third financing round with an investment of €4.2 million, which will enable the company to launch its first product for 2011 early

The presence of cataracts has been shown to influence OCT image quality.

The FDA has cleared an age-adjusted retinal nerve fibre layer thickness normative database for a proprietary ocular coherence tomography (OCT) device, Spectralis (Heidelberg Engineering).

A subretinal implant has been shown to restore some vision in patients blinded by hereditary retinal degeneration.

Spectacle correction improves distance vision during night-time driving in presbyopes but has a negative impact on near vision.

The ACI 7000 corneal inlay has shown safety and efficacy over a two-year study period in presbyopia patients, according to a study published in the Journal of Refractive Surgery.

A recent study revealed a novel push-pull training protocol that was designed to reduce sensory eye dominance (SED).

Curcumin-based treatment Norflo, has been shown to alleviate the symptoms of anterior uveitis in a recent study published in Clinical Ophthalmology, indicating a potential role for the anti-inflammatory treatment curcumin in eye inflammatory and degenerative conditions.

Pfizer has announced that Xalatan (latanoprost) has been approved by the European Commission for the reduction of elevated IOP in the treatment of paediatric patients.

Novartis has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its therapy Lucentis for the treatment of patients with diabetic macular oedema (DME).

BiCOM showcased its Diaton tonometer at this year's AAO/MEACO meeting. The pen-like, handheld, portable device can measure eye pressure through the patient's eyelid and over the sclera.

Topcon has launched two new optical coherence tomography (OCT) systems for the International market.

RXi and EyeGate have announced a collaboration focused on non-invasive ocular delivery of RNAi therapeutics. Both companies will contribute technology, expertise and resources to the partnership.

Researchers have found that giving patients a dual therapy of bimatoprost and a beta-blocker is an effective method of lowering intraocular blood pressure (IOP) in patients with open-angle glaucoma.

The Pediatric Cataract Initiative has set a deadline of 15 November for the receipt of applications for its inaugural single small research grant.

Allergan has been given FDA approval for its drug Ozurdex (dexamethasone intravitreal implant) 0.7 mg for the treatment of non-infectious ocular inflammation.

ISTA Pharmaceuticals has highlighted results from its Phase 2 clinical study on Remura dry eye solution.

ISTA Pharmaceuticals has highlighted results from its Phase 2 clinical study on Remura dry eye solution.

Acucela and Otsuka Pharmaceutical have entered into a definitive agreement for the joint development and promotion of OPA-656, an adenosine A2a receptor agonist under development for treating glaucoma.

Investigators from The Scripps Research Institute, and Thomas Reh, PhD from the University of Washington, received the highest possible scores for their proposal to investigate the regenerative potential of retinal cells, resulting in a $4.66 million NIH Transformative Award.

AstraZeneca and UCL Institute of Ophthalmology are collaborating to develop regenerative medicines for diabetic retinopathy (DR).